Jim Cramer: The tech tyranny is in excess of. These are the shares driving this marketplace

Jim Cramer: The tech tyranny is in excess of. These are the shares driving this marketplace


A employee washes a Caterpillar crawler dozer at Excellent Tractor in West Sacramento, California, on Monday, Aug. 1, 2022.

David Paul Morris | Bloomberg | Getty Images

Hardly ever have the bulls been more bashful and timid. Hardly ever have the bears been so ascendant and so mistaken. Oh absolutely sure, the bears nailed Meta Platforms (META) and strike Microsoft (MSFT) out of the park. Amazon (AMZN) flopped. So did Alphabet (GOOGL).



Supply

Howard Marks says there are very few cheap stocks: ‘Bargains come when people panic’
World

Howard Marks says there are very few cheap stocks: ‘Bargains come when people panic’

Howard Marks warned that investors hunting for bargains may be disappointed, saying markets are still far from distressed levels despite bouts of volatility. The co-founder and co-chairman of Oaktree Capital Management, who famously foresaw the dot-com bubble, said the current environment reflects an ongoing “tug of war” between bullish and bearish forces, with optimism largely […]

Read More
Investors are misreading news about the Iran war, analysts say as markets whipsaw
World

Investors are misreading news about the Iran war, analysts say as markets whipsaw

An Iranian flag flutters as a woman walks past damaged buildings amid a 10-day ceasefire between Lebanon and Israel, in the southern suburbs of Beirut, Lebanon, April 20, 2026. Marko Djurica | Reuters “Complacent” investors risk getting wrong-footed as they continue to misread developments in the Iran war, analysts said after markets reacted to the […]

Read More
Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to  billion
World

Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion

The Eli Lilly logo appears on the company’s office in San Diego, California, U.S., Nov. 21, 2025. Mike Blake | Reuters Eli Lilly will acquire biotech company Kelonia Therapeutics in a deal worth up to $7 billion, the company said Monday. Lilly will pay $3.25 billion upfront, and the remaining payments are contingent upon clinical, […]

Read More